RxDoctor Payments Data

Robert Schiff, MD

Internal Medicine · Aiea, HINPI 1235234378

Payments from drug & device makers

$2,048in general payments, 2019–2025

Across 102 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$653
  • Amarin Pharma, Inc.$350
  • Lilly USA, LLC$204
  • AstraZeneca$189
  • Astellas Pharma US Inc$150
  • Amgen$149
  • plus $353 from 11 others

What the payments were for

  • Food & beverage$2,048100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,048 in reported general payments places this provider in the 75th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$66,513
Medicare patients
152
Services billed
691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$79,808
MounjaroTirzepatide34$60,848
VascepaIcosapent Ethyl48$38,155
EntrestoSacubitril/Valsartan21$37,575
EliquisApixaban18$27,596
ProliaDenosumab11$19,296
XareltoRivaroxaban16$18,876
JanuviaSitagliptin Phosphate13$17,869
TrulicityDulaglutide12$17,512
Potassium Chloride20$8,283
OxycontinOxycodone Hcl14$7,837
Atorvastatin Calcium190$5,542
Telmisartan55$2,730
Raloxifene Hcl17$2,597
Rosuvastatin Calcium36$2,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$653$79,80842 claims
Lilly USA, LLCMounjaro, Trulicity$204$78,36046 claims
NovartisEntresto$117$37,57521 claims
AmgenProlia$149$19,29611 claims
Johnson & JohnsonXarelto$21$18,87616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →